Comment: It is essential to identify the BRCA gene in pancreatic cancer patients allowing them to be treated with an oral agent

Bookmark and Share
Published: 2 Jun 2019
Views: 396
Dr Suzanne Cole - UT Southwestern Medical Center, Dallas, USA

Dr Suzanne Cole comments on data, during a press conference at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting, from the Polo trial.

This was a phase III randomised trial in which olaparib was administered to patients with BRCA-related pancreatic cancer who had not progressed after initial chemotherapy and compared with placebo.

Watch Dr Kindler's press conference here, and interview here